Publications

BibTex format

@article{Innes:2020:10.1111/bjh.16979,
author = {Innes, AJ and Cook, LB and Marks, S and Bataillard, E and Crossette-Thambiah, C and Sivasubramaniam, G and Apperley, J and Milojkovic, D},
doi = {10.1111/bjh.16979},
journal = {British Journal of Haematology},
pages = {e198--e200},
title = {Ruxolitinib for tocilizumab-refractory severe COVID-19 infection.},
url = {http://dx.doi.org/10.1111/bjh.16979},
volume = {190},
year = {2020}
}

Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - Whilst the majority of patients with COVID-19 infection have mild self-limiting symptoms, for some the SARS-CoV2 virus can trigger a severe hyperinflammatory syndrome which is life threatening. Anti-IL6 therapy has shown promise in restraining the hyperinflammatory syndrome and while IL-6 is a pleiotropic mediatory of the inflammatory response, redundancy within inflammatory pathways means that the use of such targeted monoclonal therapy may have too restricted a repertoire in some patients. We present the case of a 53-year-old haematopoetic stem cell transplant recipient who developed a severe COVID-19 that was refractory to anti-IL6 therapy, but responded to Jak-Stat inhibition with ruxolitinib, demonstrating its safety and efficacy in this setting.
AU  - Innes,AJ
AU  - Cook,LB
AU  - Marks,S
AU  - Bataillard,E
AU  - Crossette-Thambiah,C
AU  - Sivasubramaniam,G
AU  - Apperley,J
AU  - Milojkovic,D
DO  - 10.1111/bjh.16979
EP  - 200
PY  - 2020///
SN  - 0007-1048
SP  - 198
TI  - Ruxolitinib for tocilizumab-refractory severe COVID-19 infection.
T2  - British Journal of Haematology
UR  - http://dx.doi.org/10.1111/bjh.16979
UR  - https://www.ncbi.nlm.nih.gov/pubmed/32593183
UR  - https://onlinelibrary.wiley.com/doi/abs/10.1111/bjh.16979
UR  - http://hdl.handle.net/10044/1/80831
VL  - 190
ER  -

Download

DrAndrewInnes

Contact

Location

Summary

Citation

BibTex format

RIS format (EndNote, RefMan)